SignalCorporate
Rhythm Pharmaceuticals Stock In Focus After Earnings Beat And $750 Million Financing
Earnings beat and $750 million financing drive focus.
Context
What happened: Rhythm Pharmaceuticals reported Q3 2026 results, revised its LG Chem license for bivamelagon, and secured up to US$750 million in term loan financing.
Key numbers: Q3 2026 revenue US$92.13 million versus US$51.30 million a year earlier. Quarterly net loss US$41.37 million. Up to US$750 million in term loans.
Why it matters: The amended royalty structure and new funding reshape the company's cost structure and financial flexibility, with focus on converting capital into Phase III programs while the business remains loss making.
Market: +28.0% today ($110.68), +5.4% YTD, 7.1x vol — as of 00:45 UTC
Coverage: 3 outlets in 24h
What changed
Rhythm Pharmaceuticals reported Q3 2026 results, revised its LG Chem license for bivamelagon, and secured up to US$750 million in term loan financing.
Why it matters
The amended royalty structure and new funding reshape the company's cost structure and financial flexibility, with focus on converting capital into Phase III programs while the business remains loss making.
Market: +28.0% today ($110.68), +5.4% YTD, 7.1x vol — as of 00:45 UTC